SSA
INDV icon

Schonfeld Strategic Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,835
Closed -$1.25M – 2434
2025
Q4 		$1.25M Sell
34,835
-1,297
-4% -$39.6K 0.01% 1035
2025
Q3 		$871K Buy
+36,132
New +$756K 0.01% 1442
2025
Q2 		– Sell
-178,825
Closed -$1.7M – 2262
2025
Q1 		$1.7M Buy
178,825
+43,164
+32% +$454K 0.01% 1031
2024
Q4 		$1.69M Buy
+135,661
New +$1.4M 0.01% 902
2024
Q3 		– Sell
-17,398
Closed -$280K – 2213
2024
Q2 		$280K Buy
+17,398
New +$314K ﹤0.01% 1717

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's INDV Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 34,835 shares — an estimated $1.25M sold.

Schonfeld Strategic Advisors first reported a position in INDV in Q2 2024 and held it in 5 quarters. The position peaked at $1.7M in Q1 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 34,835 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.25M.
  • Schonfeld Strategic Advisors first reported a position in Indivior Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Indivior Pharmaceuticals position peaked at $1.7M in Q1 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.